Author | dc.contributor.author | Conte Lanza, Guillermo | |
Author | dc.contributor.author | Figueroa Maureira, Gastón | es_CL |
Admission date | dc.date.accessioned | 2009-07-09T17:27:56Z | |
Available date | dc.date.available | 2009-07-09T17:27:56Z | |
Publication date | dc.date.issued | 2008-12 | |
Cita de ítem | dc.identifier.citation | REVISTA MEDICA DE CHILE, V.: 136, issue: 12, p.: 1528-1534, DEC 2008. | en |
Identifier | dc.identifier.issn | 0034-9887 | |
Identifier | dc.identifier.uri | https://repositorio.uchile.cl/handle/2250/128043 | |
Abstract | dc.description.abstract | Hospitalized patients with cancer have a high risk
of venous thromboembolism (VTE). Aim: To study the frequency of VTE and its risk factors in
hospitalized patients with cancer. Material and methods: Retrospective analysis of clinical
records of patients with cancer, hospitalized at a university hospital between 2002 and 2004.
Patients with the diagnosis of VTE at admission or using anticoagulants, were excluded from
the analysis. Results: The medical records of 366 patients were reviewed. Fifty three percent
had a digestive cancer, 19% lung cancer, 10% breast cancer and 18% had a tumor of other
origin. In 77%, the tumor was in an advanced stage. The most common admission diagnoses
were pneumonia, vomiting and dehydration, gastrointestinal bleeding and urinary infection.
In 125 patients (34%) pharmacological thrombo-prophylaxis was not used and 242 (66%)
received regular or low molecular weight heparin. VTE was detected in 11 patients (3%) and
was significantly more common among patients not receiving thrombo prophylaxis compared
to those receiving heparin (6.4% and 1.2%, respectively, p =0.014). Factors associated to VTE
were a history of previous VTE with an odds ratio (OR) of 12.9 (p <0.01), obesity with an OR of
13.3 (p <0.01), recent chemotherapy with an OR of 6.9 (p =0.01). The use of pharmacological
thromboprophylaxis had an OR of 0.24 (p =0.05). Conclusions: Three percent of patients in
this series had VTE during the hospitalization. Pharmacological thrombo-prophylaxis
significantly reduced the risk of VTE | en |
Patrocinador | dc.description.sponsorship | Financiamiento parcial por parte de Laboratorio Pfizer | en |
Lenguage | dc.language.iso | es | en |
Publisher | dc.publisher | SOC MEDICA SANTIAGO | en |
Keywords | dc.subject | Fibrinolytic agents | en |
Título | dc.title | Frecuencia de tromboembolismo venoso en pacientes hospitalizados con cáncer. Factores de riesgo y eficacia de la tromboprofilaxis farmacológica | en |
Document type | dc.type | Artículo de revista | |